{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"43"}],"units":"Participants"}],"description":"The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria","groups":[{"description":"PCI-32765 420 mg per day\n\nPCI-32765","id":"OG000","title":"Cohort 1"},{"description":"PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG001","title":"Cohort 2"},{"description":"PCI-32765 840 mg per day\n\nPCI-32765","id":"OG002","title":"Cohort 3"},{"description":"PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG003","title":"Cohort 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"From the date of first study treatment until disease progression per IMWG, up to 60 months","title":"The Clinical Benefit Response (CBR)","type":"PRIMARY","unitOfMeasure":"Participants"}